![Rainer Kramer](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Rainer Kramer
Corporate Officer/Principal presso IMMATICS N.V.
Patrimonio netto: 4 M $ in data 30/06/2024
Posizioni attive di Rainer Kramer
Società | Posizione | Inizio | Fine |
---|---|---|---|
IMMATICS N.V. | Corporate Officer/Principal | 01/01/2012 | - |
Immatics Biotechnologies GmbH
![]() Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Corporate Officer/Principal | 01/04/2012 | - |
Immatics US, Inc.
![]() Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | Direttore/Membro del Consiglio | - | - |
iOmx Therapeutics AG
![]() iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | Direttore/Membro del Consiglio | 20/07/2022 | - |
Storia della carriera di Rainer Kramer
Precedenti posizioni note di Rainer Kramer
Società | Posizione | Inizio | Fine |
---|---|---|---|
Signature Diagnostics AG
![]() Signature Diagnostics AG Pharmaceuticals: MajorHealth Technology Signature Diagnostics AG operates as a molecular diagnostics company. It discovers, validates and develops novel diagnostic products that predict outcome and drug response in patients with colorectal cancer, non-small cell lung cancer and ovarian cancer. The company was founded by André Rosenthal in 2004 and is headquartered in Potsdam, Germany. | Corporate Officer/Principal | 01/09/2010 | 01/05/2012 |
Shire Orphan Therapies GmbH
![]() Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | Corporate Officer/Principal | 01/01/2003 | 01/08/2009 |
MORPHOSYS AG | Corporate Officer/Principal | 01/01/1997 | 01/01/2003 |
AMGEN INC. | Corporate Officer/Principal | - | - |
Formazione di Rainer Kramer
University of Regensburg | Undergraduate Degree |
Max Planck Institute of Neurobiology | Doctorate Degree |
Statistiche
Distribuzione geografica
Germania | 9 |
Stati Uniti | 3 |
Posizioni
Corporate Officer/Principal | 6 |
Director/Board Member | 2 |
Undergraduate Degree | 1 |
Settori
Health Technology | 9 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
MORPHOSYS AG | Health Technology |
AMGEN INC. | Health Technology |
IMMATICS N.V. | Health Technology |
Aziende private | 5 |
---|---|
Signature Diagnostics AG
![]() Signature Diagnostics AG Pharmaceuticals: MajorHealth Technology Signature Diagnostics AG operates as a molecular diagnostics company. It discovers, validates and develops novel diagnostic products that predict outcome and drug response in patients with colorectal cancer, non-small cell lung cancer and ovarian cancer. The company was founded by André Rosenthal in 2004 and is headquartered in Potsdam, Germany. | Health Technology |
Immatics Biotechnologies GmbH
![]() Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
Shire Orphan Therapies GmbH
![]() Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | Health Technology |
Immatics US, Inc.
![]() Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | Health Technology |
iOmx Therapeutics AG
![]() iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | Health Technology |
- Borsa valori
- Insiders
- Rainer Kramer
- Esperienza